Corallodiscus flabellata B. L. Burtt extract alleviates lipopolysaccharide/D-galactosamine-induced acute liver failure and brain injury by inhibiting oxidative stress, apoptosis, and inflammation

Document Type: Original Article


1 College of Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China

2 The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Zhengzhou 450046, China



Objective(s): Corallodiscus flabellata B. L. Burtt (CF) is distributed along liver meridian, with a possible beneficial effect in the progression of acute liver failure. Therefore, the present study investigates the effect of CF extract on rats with acute liver failure.
Materials and Methods: Rats were divided into four experimental groups: Control, Lipopolysaccharide (LPS)/D-Galactosamine (D-GalN) (L/D), Wu Ling Powder + L/D (WLP+L/D) and CF + L/D. Animals were gavage for 7 days, after which all animals except the control group were injected intraperitoneally with LPS and D-GalN to induce acute liver failure. Subsequently, the urine was collected for the next 8 hr, and the liver pathological changes were observed. The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), inflammatory factor and oxidative stress-related indicators were measured. The levels of reactive oxygen species (ROS), apoptosis marker in the liver, water content and aquaporin (AQPs) in the brain were detected. The concentration of ions and osmolality of urine and serum were determined.
Results: The results show that CF significantly improved the damage of liver and brain tissue, and reversed the changes of serum ALT, AST, inflammatory factor and Cl-. It modulated oxidative stress-related indicators, reduced the content of ROS, apoptosis markers, water content, the level of Cl- ions and osmolality in the urine and the expression of AQP1, and AQP4 in the brain, and increased the urine output.
Conclusion: It was found that the CF extract could alleviate the L/D induced acute liver failure by regulating the hepatocyte apoptosis and AQPs expression in the brain.


1. Bunchorntavakul C, Reddy KR. Acute liver failure. Clin Liver Dis 2017; 21:769-792.
2. Lv H, Qi Z, Wang S, Feng H, Deng X, Ci X. Asiatic acid exhibits anti-inflammatory and antioxidant activities against lipopolysaccharide and d-galactosamine-induced fulminant hepatic failure. Front Immunol 2017; 8:785-797.
3. Thawley V. Acute liver injury and failure. Vet Clin North Am Small Anim Pract 2017; 47:617-630.
4. Rao Y. Study on the chemical constituents and their tyrosinase inhibiton of Corallodiscus flabellatus [Master]: Kunming University of Science and Technology; 2012; 06:19-58.
5. Chinese Flora Editing Committee. Flor reipublicae popularis sinicae 1900; 69:235.
6. Butterworth RF. The concept of “the inflamed brain” in acute liver failure: mechanisms and new therapeutic opportunities. Metab Brain Dis 2016; 31:1283-1287.
7. Bosoi CR, Rose CF. Brain edema in acute liver failure and chronic liver disease: similarities and differences. Neurochem Int 2013; 62:446-457.
8. Furuya S, Kono H, Hara M, Hirayama K, Sun C, Fujii H. Interleukin 17A plays a role in lipopolysaccharide/D-galactosamine-induced fulminant hepatic injury in mice. J Surg Res 2015; 199:487-493.
9. Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, et al. NF-κB restricts inflammasome activation via elimination of damaged mitochondria. Cell 2016; 164:896-910.
10. Zheng XF, Hu XY, Ma B, Fang H, Zhang F, Mao YF, et al. Interleukin-35 attenuates D-galactosamine/lipopolysaccharide-induced liver injury via enhancing interleukin-10 production in kupffer cells. Front Pharmacol 2018; 9:959-967.
11. Hammerich L, Tacke F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clin Exp Gastroenterol 2014; 7:297-306.
12. Rama Rao KV, Jayakumar AR, Tong X, Alvarez VM, Norenberg MD. Marked potentiation of cell swelling by cytokines in ammonia-sensitized cultured astrocytes. J Neuroinflammation 2010; 7:66-74.
13. Engelmann C, Adebayo D, Oria M, De Chiara F, Novelli S, Habtesion A, et al. Recombinant alkaline phosphatase prevents acute on chronic liver failure. Sci Rep 2020; 10:389-402.
14. Guo Y, Zhang Y, Hong K, Luo F, Gu Q, Lu N, et al. AMPK inhibition blocks ROS-NFkappaB signaling and attenuates endotoxemia-induced liver injury. PLoS One 2014; 9:e86881.
15. Cho KA, Woo SY, Seoh JY, Han HS, Ryu KH. Mesenchymal stem cells restore CCl4-induced liver injury by an antioxidative process. Cell Biol Int 2012; 36:1267-1274.
16. Huang H, Zhang X, Li J. Protective effect of oroxylin A against lipopolysaccharide and/or D-galactosamine-induced acute liver injury in mice. J Surg Res 2015; 195:522-528.
17. Wołonciej M, Milewska E, Roszkowska-Jakimiec W. Trace elements as an activator of anti-oxidant enzymes. Postepy Hig Med Dosw (Online) 2016; 70:1483-1498.
18. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis 2014; 5:e1437.
19. Jia YN, Lu HP, Peng YL, Zhang BS, Gong XB, Su J, et al. Oxyresveratrol prevents lipopolysaccharide/d-galactosamine-induced acute liver injury in mice. Int Immunopharmacol 2018; 56:105-112.
20. Wang LH, Wang ZL, Chen WY, Chen MJ, Xu GY. The glymphatic system: concept, function and research progresses. Sheng Li Xue Bao 2018; 70:52-60.
21. Leitão RA, Sereno J, Castelhano JM, Gonçalves SI, Coelho-Santos V, Fontes-Ribeiro C, et al. Aquaporin-4 as a new target against methamphetamine-induced brain alterations: focus on the neurogliovascular unit and motivational behavior. Mol Neurobiol 2018; 55:2056-2069.
22. Kim J, Kim YH, Kim J, Park DY, Bae H, Lee DH, et al. YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation. J Clin Invest 2017; 127:3441-3461.
23. Hirt L, Fukuda AM, Ambadipudi K, Rashid F, Binder D, Verkman A, et al. Improved long-term outcome after transient cerebral ischemia in aquaporin-4 knockout mice. J Cereb Blood Flow Metab 2017; 37:277-290.
24. Huang J, Lu WT, Sun SQ, Yang ZB, Huang SQ, Gan SW, et al. Upregulation and lysosomal degradation of AQP4 in rat brains with bacterial meningitis. Neurosci Lett 2014; 566:156-161.
25. Papadopoulos MC, Verkman AS. Aquaporin-4 gene disruption in mice reduces brain swelling and mortality in pneumococcal meningitis. J Biol Chem 2005; 280:13906-13912.
26. Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. Pediatric Nephrology 2007; 22:778-784.
27. Roşu GC, Pirici I, Istrate-Ofiţeru AM, Iovan L, Tudorică V, Mogoantă L, et al. Expression patterns of aquaporins 1 and 4 in stroke. Rom J Morphol Embryol 2019; 60:823-830.
28. Owler BK, Pitham T, Wang D. Aquaporins: relevance to cerebrospinal fluid physiology and therapeutic potential in hydrocephalus. Cerebrospinal Fluid Res 2010; 7:15-27.
29.Kan Y, Zeng M, Zhang B, Li B, Wang S, Wang Y, et al. Corallodiscus flabellata B.L. Burtt extracts stimulate diuretic activity and regulate the renal expression of aquaporins. Evid Based Complement Alternat Med 2020; 2020:602-612.